【藥品性質提示】 ★LASA藥品：SYN08 Syntrend 錠劑 粉 6.25mg (形似) 點擊看LASA藥品外觀比較圖

高血壓 (Alpha-blocker) 高血壓 (Beta-blocker) 治療心衰竭 治療心絞痛 Carvedilol is a nonselective beta-adrenergic blocking agent with alpha-1 blocking activity, moderate membrane stabilizing activity, no intrinsic sympathomimetic activity, and high lipid solubility. Carvedilol is effective in the treatment of mild-to-moderate hypertension, angina, and congestive heart failure.

Numerous studies have shown that oral carvedilol is effective in the treatment of mild to moderate hypertension. Carvedilol has been shown to reduce infarct size in animals. Carvedilol may be given as adjunctive therapy with diuretics, angiotensin-converting- enzyme inhibitors, and with or without digoxin in patients with CHF. Carvedilol has been shown to be effective in the treatment of angina pectoris. The ability of carvedilol to reduce afterload may improve left ventricular function in patients with angina.

The drug is extensively metabolized in the liver and primarily excreted via the feces; the elimination half-life of carvedilol is 6 to 8 hours.

Bronchial asthma or chronic obstructive pulmonary disease, cardiogenic shock, hypersensitivity, overt cardiac failure, second and third degree AV block, severe sinus bradycardia, sick sinus syndrome, and severe liver failure

C

Carvedilol is highly lipophilic with a large volume of distribution, and therefore may accumulate in human breast milk.

The most common adverse effect is dizziness; other adverse effects include fatigue, hypotension, bradycardia, headache, bronchospasm, and skin rash.
Post-marketing adverse reactions:
1.Cardiac disorders: Sinus arrest may occur in patients at risk (e.g.,elderly patients or those with existing bradycardia, sinoatrial node dysfunction, or atrioventricular conduction block).
2.Potentiation/masking of hypoglycemia: Due to its β-blocking properties, there is also a potential for masking symptoms of hypoglycemia.
3. CNS effects: Beta-blockers may cause CNS effects such as fatigue, sleep disorder, insomnia, and vivid dreams.
4.Renal and urinary disorders: Cases of urinary incontinence in women have
been reported, with recovery observed after discontinuation of the medication.
5.Skin and subcutaneous tissue disorders: Alopecia, severe skin reactions (TEN,SJS).
<20240415>

Adults: Hypertension, 6.25 mg PO BID may be increase to 12.5-25 mg BID; CHF, 3.125 mg PO BID may be doubled every 2 weeks up to a maximum dose of 25-50 mg BID; dose reductions are suggested in liver disease